Literature DB >> 31049328

Uveal Melanoma in Ireland.

Caroline Baily1, Valerie O'Neill1, Mary Dunne2, Moya Cunningham3, Giuseppe Gullo4, Susan Kennedy1, Paul M Walsh5, Sandra Deady5, Noel Horgan1.   

Abstract

PURPOSE: To report the clinical features and epidemiology of uveal melanoma in Ireland.
METHODS: This was an observational study of 253 patients with a new diagnosis of uveal melanoma between June 2010 and December 2015. Main outcome measures included demographics, clinical features, age-adjusted incidence, relative survival, overall survival, and distant metastases-free survival.
RESULTS: The mean patient age was 61.7 years. Tumour location was choroidal in 82%, ciliochoroidal in 9%, iridociliary in 2%, and iris in 7%. Treatment modalities included brachytherapy (ruthenium-106 and iodine-125 [64%]), enucleation (27%), and proton beam radiation (8%). The mean age-adjusted incidence of uveal melanoma in Ireland from 2010 to 2015 was 9.5 per million of the population (95% confidence interval [CI]: 8.4-10.7). Four-year relative survival was 81.3% (95% CI: 72.8-87.3). Four-year overall survival was 84% (95% CI: 78-90) and 4-year distant metastases-free survival was 79% (95% CI: 73-86).
CONCLUSION: Based on this data, the incidence of uveal melanoma in Ireland is high when compared with other reported incidence rates in Europe and worldwide. Relative and observed survival were in keeping with other reported European survival rates.

Entities:  

Keywords:  Brachytherapy; Choroid; Epidemiology; Incidence; Melanoma; Survival

Year:  2018        PMID: 31049328      PMCID: PMC6489068          DOI: 10.1159/000492391

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  55 in total

1.  Epidemiology of ocular melanoma. Incidence and geographic relationship in Ohio (1967-1977).

Authors:  F H Davidorf; J A Knupp
Journal:  Ohio State Med J       Date:  1979-09

2.  Eye color and cutaneous nevi predict risk of ocular melanoma in Australia.

Authors:  C M Vajdic; A Kricker; M Giblin; J McKenzie; J Aitken; G G Giles; B K Armstrong
Journal:  Int J Cancer       Date:  2001-06-15       Impact factor: 7.396

3.  Malignant neoplasms of the eye in Norway. Incidence, treatment and prognosis.

Authors:  T MORK
Journal:  Acta Ophthalmol (Copenh)       Date:  1961

4.  Occupational risk factors, ultraviolet radiation, and ocular melanoma: a case-control study in France.

Authors:  P Guénel; L Laforest; D Cyr; J Févotte; S Sabroe; C Dufour; J M Lutz; E Lynge
Journal:  Cancer Causes Control       Date:  2001-06       Impact factor: 2.506

5.  Sun exposure predicts risk of ocular melanoma in Australia.

Authors:  Claire M Vajdic; Anne Kricker; Michael Giblin; John McKenzie; Joanne Aitken; Graham G Giles; Bruce K Armstrong
Journal:  Int J Cancer       Date:  2002-09-10       Impact factor: 7.396

6.  Incidence of uveal melanoma in Sweden from 1960 to 1998.

Authors:  Louise Bergman; Stefan Seregard; Bo Nilsson; Ulrik Ringborg; Göran Lundell; Boel Ragnarsson-Olding
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-08       Impact factor: 4.799

7.  Very long-term prognosis of patients with malignant uveal melanoma.

Authors:  Emma Kujala; Teemu Mäkitie; Tero Kivelä
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-11       Impact factor: 4.799

8.  Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities.

Authors:  Frank Tschentscher; Johannes Hüsing; Tanja Hölter; Elisabeth Kruse; Irina Gana Dresen; Karl-Heinz Jöckel; Gerasimos Anastassiou; Harald Schilling; Norbert Bornfeld; Bernhard Horsthemke; Dietmar Rudolf Lohmann; Michael Zeschnigk
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

9.  Incidence of uveal melanoma in the United States: 1973-1997.

Authors:  Arun D Singh; Allan Topham
Journal:  Ophthalmology       Date:  2003-05       Impact factor: 12.079

10.  The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study.

Authors:  R Folberg; J Pe'er; L M Gruman; R F Woolson; G Jeng; P R Montague; T O Moninger; H Yi; K C Moore
Journal:  Hum Pathol       Date:  1992-11       Impact factor: 3.466

View more
  9 in total

1.  Uveal melanoma-associated survival in Scotland.

Authors:  Aaron Jamison; Lesley A Bhatti; Manvi M Sobti; Vikas Chadha; Paul Cauchi; Ewan G Kemp
Journal:  Eye (Lond)       Date:  2019-10-25       Impact factor: 3.775

2.  Long-term relative survival in uveal melanoma: a systematic review and meta-analysis.

Authors:  Gustav Stålhammar; Christina Herrspiegel
Journal:  Commun Med (Lond)       Date:  2022-03-01

3.  Quality of Life in Uveal Melanoma Patients in Ireland: A Single-Centre Survey.

Authors:  Olya Scannell; Valerie O'Neill; Mary Dunne; Caroline Baily; Amira Salih; Moya Cunningham; Noel Horgan
Journal:  Ocul Oncol Pathol       Date:  2019-08-22

4.  Soluble HLA in the Aqueous Humour of Uveal Melanoma Is Associated with Unfavourable Tumour Characteristics.

Authors:  Annemijn P A Wierenga; Gülçin Gezgin; Els van Beelen; Michael Eikmans; Marijke Spruyt-Gerritse; Niels J Brouwer; Mieke Versluis; Robert M Verdijk; Sjoerd G van Duinen; Marina Marinkovic; Gregorius P M Luyten; Martine J Jager
Journal:  Cancers (Basel)       Date:  2019-08-18       Impact factor: 6.639

5.  Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor.

Authors:  Husvinee Sundaramurthi; Sandra García-Mulero; Valentina Tonelotto; Kayleigh Slater; Simone Marcone; Josep M Piulats; Ronald William Watson; Desmond J Tobin; Lasse D Jensen; Breandán N Kennedy
Journal:  Cancers (Basel)       Date:  2022-02-03       Impact factor: 6.639

6.  A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma.

Authors:  Elias A T Koch; Niels Schaft; Mirko Kummer; Carola Berking; Gerold Schuler; Kenichiro Hasumi; Jan Dörrie; Beatrice Schuler-Thurner
Journal:  Front Immunol       Date:  2022-02-04       Impact factor: 7.561

7.  Clinical determinants of long-term survival in metastatic uveal melanoma.

Authors:  Elias A T Koch; Anne Petzold; Anja Wessely; Edgar Dippel; Michael Erdmann; Lucie Heinzerling; Bettina Hohberger; Harald Knorr; Ulrike Leiter; Friedegund Meier; Peter Mohr; Farnaz Rahimi; Beatrice Schell; Max Schlaak; Patrick Terheyden; Beatrice Schuler-Thurner; Selma Ugurel; Jochen Utikal; Julio Vera; Michael Weichenthal; Fabian Ziller; Carola Berking; Markus V Heppt
Journal:  Cancer Immunol Immunother       Date:  2021-10-28       Impact factor: 6.630

Review 8.  Hindsight: Review of Preclinical Disease Models for the Development of New Treatments for Uveal Melanoma.

Authors:  Caoimhe Goldrick; Letizia Palanga; Bobby Tang; Grace Mealy; John Crown; Noel Horgan; Susan Kennedy; Naomi Walsh
Journal:  J Cancer       Date:  2021-06-04       Impact factor: 4.207

Review 9.  Iris Colour and the Risk of Developing Uveal Melanoma.

Authors:  Laurien E Houtzagers; Annemijn P A Wierenga; Aleid A M Ruys; Gregorius P M Luyten; Martine J Jager
Journal:  Int J Mol Sci       Date:  2020-09-28       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.